Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial.

from Latest Science News -- ScienceDaily https://ift.tt/qIVl8sc

Comments

Popular posts from this blog

Seismic study reveals key reason why Patagonia is rising as glaciers melt

New method to detect and visualize sperm cells recovered from forensic evidence